WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA

Clinical trials for WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA trials appear

Sign up with your email to follow new studies for WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare, Fast-Growing tumors: First-of-its-Kind trial launches

Disease control Recruiting now

This study is testing whether a combination of two existing cancer drugs, lenvatinib and pembrolizumab, can help control a rare and aggressive type of neuroendocrine tumor. It will enroll 29 adults with a specific, fast-growing tumor type that has spread or cannot be removed by s…

Matched conditions: WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA

Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA

Get alerted when new WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA trials appear

New hope for rare, Fast-Growing tumors: First-of-its-Kind trial launches